10 Must-Buy US Stocks to Buy Right Now

In this article, we look at the 10 Must-Buy US Stocks to Buy Right Now.

For some time, investors worried that the geopolitical conflict in the Middle East might drag on. That concern eased, at least temporarily, after U.S. President Trump announced on April 7 via Truth Social that hostilities would pause for two weeks. The possibility that oil would resume flowing through the Strait of Hormuz sent crude into a sharp decline: Brent crude tumbled roughly 13% to $94.80 a barrel, and US-traded oil, or WTI, fell more than 15% to $95.75. Stocks, too, weren’t left behind. The Dow Jones Industrial Average climbed more than 1,320 points, or 2.85%, and the Nasdaq Composite gained nearly 620 points, a 2.8% rise. The S&P 500, which had been nursing steep March losses, effectively erased them in a single session.

The initial euphoria, however, is being tested. By April 9, US stock futures had retreated as both sides accused each other of violating the truce. The pause, according to President Trump, is conditional on Iran’s full reopening of the Strait of Hormuz. However, a Financial Times analysis showed that commercial shipping through the Strait has barely resumed, and that the limited traffic that has moved is overwhelmingly tied to Tehran.

“At least nine of the roughly 14 vessels to transit the chokepoint since the pause in fighting have Iranian ties, including ships calling at Iranian ports or flying the country’s flag,” the FT stated.

Regardless, Andrew Tyler, JPMorgan’s head of global market intelligence, believes the ceasefire will “trigger a re-risking potentially similar to the post-Liberation Day pivot.” He added that breaching 7,000 on the S&P 500 “feels likely as euphoria returns to markets.” For Ed Yardeni of Yardeni Research, the probability of a US recession is lower. He lowered this probability to 20% from 35%, citing data that showed the economy was strong heading into the conflict.

With that in mind, this article highlights 10 names best positioned to capitalize on the current environment.

Our Methodology

To identify the 10 Must-Buy US Stocks to Buy Right Now, we used the Finviz stock screener to compile an initial group of US-listed equities. From this pool, we focused on well-known companies that had delivered year-to-date returns exceeding 30% as of April 12, 2026. All the stocks carry Strong Buy ratings from analysts. We determined the stocks’ popularity using hedge fund holdings data from Q4 2025 13F filings available in Insider Monkey’s database. The final list is ranked in ascending order by the number of hedge fund holders.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

Must-Buy US Stocks to Buy Right Now

10. Adeia Inc. (NASDAQ:ADEA)

Number of Hedge Fund Holders: 20

Year-To-Date Performance: 52.84%

Adeia Inc. (NASDAQ:ADEA) is one of the must-buy US stocks to buy right now. On April 4, Adeia Inc. (NASDAQ:ADEA) announced that its subsidiaries filed a patent infringement lawsuit against DISH Network in the U.S. District Court of Colorado. The company claims DISH is using five of its media patents without authorization, covering technologies for content discovery and digital TV experiences. Adeia said it remains open to resolution but is prepared to pursue the matter legally.

Adeia Inc. projects 2026 revenue between $395 million and $435 million, with adjusted EBITDA expected to reach up to $245 million. Analysts continue to see upside, with price targets ranging from $28 to $40.

Adeia’s portfolio spans more than 13,750 patents across media and semiconductors. The company has previously engaged in litigation with Disney and AMD, underscoring the importance of its intellectual property in the industry. It is also reducing debt and building recurring semiconductor revenue through hybrid bonding technology.

At the Roth Conference in March, Adeia highlighted its shift from legacy pay‑TV toward OTT streaming, e‑commerce, and semiconductor innovations. Deals with Amazon, Disney, and AMD support this transition, while new technologies like RapidCool thermal management are in late‑stage development. Management expects semiconductor revenue to reach $100 million annually, positioning Adeia for long‑term growth beyond traditional media.

Adeia Inc. (NASDAQ:ADEA) and its subsidiaries operate as a global intellectual property licensing company, focused on media and semiconductor technologies across the U.S., Canada, Asia, Europe, the Middle East, and other international markets.

9. Cenovus Energy Inc. (NYSE:CVE)

Number of Hedge Fund Holders: 46

Year-To-Date Performance: 51.65%

Cenovus Energy Inc. (NYSE:CVE) is one of the must-buy US stocks to buy right now. On March 25, S&P Global Ratings revised its outlook on Cenovus Energy Inc. (NYSE:CVE) from negative to stable, while affirming its BBB issuer credit and unsecured debt ratings. The ratings giant cited a meaningfully improved financial risk profile built on operational progress, asset disposals, and stronger oil price assumptions.

One of the key factors that S&P considered was Cenovus’s closing of its C$8.4 billion acquisition of MEG Energy in November 2025. The ratings firm also noted that Cenovus achieved first production from three of its five key growth projects in the second half of 2025 and sold its non-operated refinery stakes. Cenovus did all these while staying committed to its deleveraging targets, S&P noted.

The other key input into S&P’s revised outlook was the agency’s own updated oil price forecast. On March 16, S&P raised its West Texas Intermediate, or WTI, crude oil price assumption by $15 per barrel to $75/bbl for the remainder of 2026. This action was supported by the ongoing conflict in the Middle East, which the agency said is a key tailwind that meaningfully strengthened Cenovus’ cash flow projections.

Those inputs put together, S&P now expects Cenovus’ funds from operations, or FFO, to debt to land in the 70%-80% range over the next two years. The metric should also remain comfortably above 45% even under midcycle commodity assumptions, the agency said.

Cenovus Energy Inc. (NYSE:CVE) is an integrated energy company engaged in the production, refining, and marketing of crude oil, natural gas, and related products. It produces crude oil and natural gas from oil sands and conventional assets, and refines these into products such as gasoline, diesel, and jet fuel through its downstream operations.

8. Qnity Electronics, Inc. (NYSE:Q)

Number of Hedge Fund Holders: 48

Year-To-Date Performance: 59.07%

Qnity Electronics, Inc. (NYSE:Q) is one of the must-buy US stocks to buy right now. On April 6, Qnity Electronics, Inc. (NYSE:Q) announced it will release its first‑quarter 2026 financial results before the market opens on Tuesday, May 12, 2026.

Earlier on March 11, Qnity Electronics, Inc. opened a new 385,000-square-foot semiconductor manufacturing facility in Newark, Delaware. The ribbon-cutting ceremony was attended by Delaware Governor Matt Meyer and other government and community leaders.

The company said that the facility’s first manufacturing line is dedicated to producing components for chemical mechanical planarization (CMP) pads. These are the polishing discs used to smooth a chip’s surface during fabrication. Qnity noted that artificial-intelligence chip production specifically requires more CMP steps per wafer than traditional chips. As such, this capacity addition is particularly relevant to where the semiconductor industry is heading.

Chief Operations and Engineering Officer John Singer framed the move as part of Qnity’s “local-for-local” operating model. This is the idea of placing facilities and personnel close to customers to enable better collaboration and a more dependable supply chain. Singer added that Qnity’s globally networked operations allow it to “optimize production, sourcing, and technology from around the world” to serve customers wherever they are.

The Delaware facility is one piece of a broader capacity buildout. On March 6, for instance, Qnity announced a $61.5 million acquisition of a semiconductor facility in Taiwan. This facility, the company said, will support advanced chip manufacturing applications, including production areas, clean rooms, research labs, and warehousing space.

Qnity Electronics, Inc. (NYSE:Q) provides materials and solutions used in semiconductor manufacturing and electronics production. It supplies products such as CMP pads and slurries, photoresists, advanced coatings, thermal interface materials, and electronic laminates used in chip fabrication and packaging.

7. Monolithic Power Systems, Inc. (NASDAQ:MPWR)

Number of Hedge Fund Holders: 50

Year-To-Date Performance: 47.21%

Monolithic Power Systems, Inc. (NASDAQ:MPWR) is one of the must-buy US stocks to buy right now. On March 19, Truist Securities analyst William Stein reiterated a Buy rating on Monolithic Power Systems, Inc. (NASDAQ:MPWR) and maintained his $1,396 price target. This move came right after Truist met with Monolithic’s executives.

Stein noted that during the meeting, management pointed to the company’s expanding design win pipeline. These design wins are rooted in Monolithic’s growing footprint in AI infrastructure. Interestingly, this aspect also happens to have been key in Truist’s stance on Monolithic in an earlier note, posted on December 19, where the firm raised its price target to $1,375 from $1,163 and left the Buy rating unchanged.

In that note, Truist noted that Monolithic was benefiting from next-generation GPU and XPU platforms that require higher-density power delivery. The note added that the company’s proprietary DC to DC converters and vertical power delivery solutions were targeting a market opportunity of more than $4 billion in AI data centers.

In that December note, Truist had also highlighted Monolithic’s emerging role in Power Distribution Boards for hyperscale AI clusters. Management saw these wins as structural, not cyclical, the firm noted.

In the current note, Truist noted that management came out of the March 18 meeting with high confidence in design wins, customer positioning, and margins. That optimism gave Truist the confidence to leave its calendar year 2027 EPS estimate unchanged at $25.39. In fact, Stein stated that the risk in his firm’s model is tilted toward the upside rather than the downside. Put simply, Truist believes there is a greater chance of Monolithic beating those estimates than missing them.

Monolithic Power Systems, Inc. (NASDAQ:MPWR) is a semiconductor company that designs and supplies power management solutions for electronic systems. It develops analog and mixed-signal integrated circuits, including DC-DC converters, power modules, battery management systems, and motor drivers used in data centers, consumer electronics, automotive systems, and industrial equipment.

6. Roivant Sciences Ltd. (NASDAQ:ROIV)

Number of Hedge Fund Holders: 52

Year-To-Date Performance: 31.26%

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the must-buy US stocks to buy right now. On April 2, Roivant Sciences Ltd. (NASDAQ:ROIV) said its subsidiary Priovant Therapeutics had started enrolling patients in a Phase 2b/3 trial of brepocitinib for lichen planopilaris (LPP). LPP is a severe inflammatory hair loss condition and brepocitinib treats that inflammation.

Roivant said that the trial structure starts with a 72-patient Phase 2b segment to refine dosing and endpoints, then flows directly into a 270-patient Phase 3 without interruption. It added that the primary endpoint being targeted is an Investigator’s Global Assessment (IGA) score of 0 or 1 with a two-point reduction. This is a more defined measure than previous LPP studies, the company noted.

Priovant CEO Ben Zimmer said brepocitinib’s mechanism is well-suited for LPP. This is because the disease is driven by TH1-polarized T-cell activity, which is the exact biology the drug is designed to suppress.

Separately, Roivant’s Immunovant unit reported that batoclimab failed to meet the primary endpoint in two Phase 3 studies testing the drug in thyroid eye disease (TED). TED is a condition where the immune system attacks the tissue behind the eyes, causing them to bulge outward. Unfortunately, the drug didn’t reduce eye bulging enough to meet the study’s goal. Immunovant is now reconsidering its future development, Roivant said.

Roivant Sciences Ltd. (NASDAQ:ROIV) develops and commercializes medicines through a network of subsidiary companies. It acquires or in-licenses drug candidates and advances them through clinical development across multiple therapeutic areas, including immunology, dermatology, and rare diseases.

Click to continue reading and see the 5 Must-Buy US Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.